Potential role of NKT regulatory cell ligands for the treatment of immune mediated colitis

World Journal of Gastroenterology

Volumn 13, Issue 44, 2007, Pages 5799-5804

  Haj, Madi El ^a   Ya'acov, Ami Ben ^a   Lalazar, Gadi ^a   Ilan, Yaron ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Colitis; Immunomodulatory; Inflammatory bowel disease; Ligand; Natural killerT lymphocyte

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALPHA C GALACTOSYLCERAMIDE; ALPHA GALACTOSYLCERAMIDE; BETA GALACTOSYLCERAMIDE; BETA GLYCOLIPID; BETA LACTOSYLCERAMIDE; CD1D ANTIGEN; GAMMA INTERFERON; GLYCOLIPID; INTERLEUKIN 12; INTERLEUKIN 4; KRN 700; LIGAND; OCH; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; COLITIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; EDITORIAL; ENCEPHALOMYELITIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; LIVER CELL CARCINOMA; LYMPHOCYTE FUNCTION; MALARIA; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; METASTASIS; NATURAL KILLER CELL; NONHUMAN; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS;

EID: 36348953943     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i44.5799     Document Type: Editorial

References (73)

1. Makino Y, Kanno R, Ito T, Higashino K, Taniguchi M. Predominant expression of invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations. Int Immunol 1995; 7: 1157-1161
2. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005; 23: 877-900
3. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25: 297-336
4. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med 1994; 180: 1097-1106
5. Yu KO, Im JS, Molano A, Dutronc Y, Illarionov PA, Forestier C, Fujiwara N, Arias I, Miyake S, Yamamura T, Chang YT, Besra GS, Porcelli SA. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci USA 2005; 102: 3383-3388
6. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4: 231-237
7. Kronenberg M, Rudensky A. Regulation of immunity by self-reactive T cells. Nature 2005; 435: 598-604
8. Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol 1996; 26: 2989-2998
9. Baxter AG, Kinder SJ, Hammond KJ, Scollay R, Godfrey DI. Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 1997; 46: 572-582
10. Carnaud C, Gombert J, Donnars O, Garchon H, Herbelin A. Protection against diabetes and improved NK/NKT cell performance in NOD.NK1.1 mice congenic at the NK complex. J Immunol 2001;166:2404-2411
11. Araki M, Kondo T, Gumperz JE, Brenner MB, Miyake S, Yamamura T. Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int Immunol 2003; 15: 279-288
12. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002; 110: 793-800
13. Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 2001; 44: 1127-1138
14. Hammond KJ, Godfrey DI. NKT cells: potential targets for autoimmune disease therapy? Tissue Antigens 2002; 59: 353-363
15. Kukreja A, Maclaren NK. NKT cells and type-1 diabetes and the "hygiene hypothesis" to explain the rising incidence rates. Diabetes Technol Ther 2002; 4: 323-333
16. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Sanz M, Exley M, Wilson B, Porcelli S, Maclaren N. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109: 131-140
17. Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, Koezuka Y, Kumar V. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001; 194: 1789-1799
18. Trop S, Samsonov D, Gotsman I, Alper R, Diment J, Ilan Y. Liver-associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model. Hepatology 1999; 29: 746-755
19. Margalit M, Ilan Y, Ohana M, Safadi R, Alper R, Sherman Y, Doviner V, Rabbani E, Engelhardt D, Nagler A. Adoptive transfer of small numbers of DX5+ cells alleviates graft-versus-host disease in a murine model of semiallogeneic bone marrow transplantation: a potential role for NKT lymphocytes. Bone Marrow Transplant 2005; 35: 191-197
20. Margatit M, Shibolet O, Klein A, Elinav E, Alper R, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes. Int J Cancer 2005; 115: 443-449
21. Smyth MJ, Godfrey DI. NKT cells and tumor immunity-a double-edged sword. Nat Immunol 2000; 1: 459-460
22. Nieuwenhuis EE, Matsumoto T, Exley M, Schleipman RA, Glickman J, Bailey DT, Corazza N, Colgan SP, Onderdonk AB, Blumberg RS. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med 2002; 8: 588-593
23. Swann JB, Coquet JM, Smyth MJ, Godfrey DI. CD1-restricted T cells and tumor immunity. Curr Top Microbiol Immunol 2007; 314: 293-323
24. Seino K, Motohashi S, Fujisawa T, Nakayama T, Taniguchi M. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci 2006; 97: 807-812
25. Seino K, Fujii S, Harada M, Motohashi S, Nakayama T, Fujisawa T, Taniguchi M. Valpha14 NKT cell-mediated antitumor responses and their clinical application. Springer Semin Immunopathol 2005; 27: 65-74
26. Exley M, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J Exp Med 1997; 186: 109-120
27. + alpha beta T cell pool. J Immunol 1999; 162: 366-371
28. Savage PB, Teyton L, Bendelac A. Glycolipids for natural killer T cells. Chem Soc Rev 2006; 35: 771-779
29. Gulbins E, Li PL. Physiological and pathophysiological aspects of ceramide. Am J Physiol Regul Integr Comp Physiol 2006; 290: R11-R26
30. Saito M, Rosenberg A. The fate of glucosylceramide (glucocerebroside) in genetically impaired (lysosomal beta-glucosidase deficient) Gaucher disease diploid human fibroblasts. J Biol Chem 1985; 260: 2295-2300
31. Marti GE, Ryan ET, Papadopoulos NM, Filling-Katz M, Barton N, Fleischer TA, Rick M, Gralnick HR. Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease. Am J Hematol 1988; 29: 189-194
32. Matsuki N, Stanic AK, Embers ME, Van Kaer L, Morel L, Joyce S. Genetic dissection of V alpha 14J alpha 18 natural T cell number and function in autoimmune-prone mice. J Immunol 2003; 170: 5429-5437
33. Morita M, Motoki K, Akimoto K, Natori T, Sakai T, Sawa E, Yamaji K, Koezuka Y, Kobayashi E, Fukushima H. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem 1995; 38: 2176-2187
34. Cantu C 3rd, Benlagha K, Savage PB, Bendelac A, Teyton L. The paradox of immune molecular recognition of alpha-galactosylceramide: low affinity, low specificity for CD1d, high affinity for alpha beta TCRs. J Immunol 2003; 170: 4673-4682
35. Parekh VV, Wilson MT, Van Kaer L. iNKT-cell responses to glycolipids. Crit Rev Immunol 2005; 25: 183-213
36. Ndonye RM, Izmirian DP, Dunn MF, Yu KO, Porcelli SA, Khurana A, Kronenberg M, Richardson SK, Howell AR. Synthesis and evaluation of sphinganine analogues of KRN7000 and OCH. J Org Chem 2005; 70: 10260-10270
37. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med 2003; 198: 1631-1641
38. Ueno Y, Tanaka S, Sumii M, Miyake S, Tazuma S, Taniguchi M, Yamamura T, Chayama K. Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of valpha14 natural killer T cells in mice. Inflamm Bowel Dis 2005; 11: 35-41
39. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, Miura T, Haba T, Scherer DC, Wei J, Kronenberg M, Koezuka Y, Van Kaer L. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7: 1052-1056
40. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenk OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, Leite-De-Moraes M, Gouarin C, Zhu R, Hameg A, Nakayama T, Taniguchi M, Lepault F, Lehuen A, Bach JF, Herbelin A. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 2001; 7: 1057-1062
41. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest 2003; 112: 1211-1222
42. Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, Hansson GK, Berne GP. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 2004; 199: 417-422
43. Nakai Y, Iwabuchi K, Fujii S, Ishimori N, Dashtsoodol N, Watano K, Mishima T, Iwabuchi C, Tanaka S, Bezbradica JS, Nakayama T, Taniguchi M, Miyake S, Yamamura T, Kitabatake A, Joyce S, Van Kaer L, Once K. Natural killer T cells accelerate atherogenesis in mice. Blood 2004; 104: 2051-2059
44. Biburger M, Tiegs G. Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells. J Immunol 2005; 175: 1540-1550
45. Osman Y, Kawamura T, Naito T, Takeda K, Van Kaer L, Okumura K, Abo T. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol 2000; 30: 1919-1928
46. Brutkiewicz RR. CD1d ligands: the good, the bad, and the ugly. J Immunol 2006; 177: 769-775
47. Zhou D. The immunological function of iGb3. Curr Protein Pept Sci 2006; 7: 325-333
48. Miyake S, Yamamura T. Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseases. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 315-322
49. Zhou D, Mattner J, Cantu C 3rd, Schrantz N, Yin N, Gao Y, Sagiv Y, Hudspeth K, Wu YP, Yamashita T, Teneberg S, Wang D, Proia RL, Levery SB, Savage PB, Teyton L, Bendelac A. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004; 306: 1786-1789
50. Wu D, Xing GW, Poles MA, Horowitz A, Kinjo Y, Sullivan B, Bodmer-Narkevitch V, Plettenburg O, Kronenberg M, Tsuji M, Ho DD, Wong CH. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci USA 2005; 102: 1351-1356
51. Apostolou I, Takahama Y, Belmant C, Kawano T, Huerre M, Marchal G, Cui J, Taniguchi M, Nakauchi H, Fournie JJ, Kourilsky P, Gachelin G. Murine natural killer T(NKT) cells (correction of natural killer cells) contribute to the granulomatous reaction caused by mycobacterial cell walls. Proc Natl Acad Sci USA 1999; 96: 5141-5146
52. Emoto M, Emoto Y, Buchwalow IB, Kaufmann SH. Induction of IFN-gamma-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette Guerin. Eur J Immunol 1999; 29: 650-659
53. Kadena T, Matsuzaki G, Fujise S, Kishihara K, Takimoto H, Sasaki M, Beppu M, Nakamura S, Nomoto K. TCR alpha beta+ CD4- CD8- T cells differentiate extrathymically in an lck-independent manner and participate in early response against Listeria monocytogenes infection through interferon-gamma production. Immunology 1997; 91: 511-519
54. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C 3rd, Zhou D, Saint-Mezard P, Wang V, Gao Y, Yin N, Hoebe K, Schneewind O, Walker D, Beutler B, Teyton L, Savage PB, Bendelac A. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005; 434: 525-529
55. Kinjo Y, Kronenberg M. Valpha14i NKT cells are innate lymphocytes that participate in the immune response to diverse microbes. J Clin Immunol 2005; 25: 522-533
56. Schofield L, McConville MJ, Hansen D, Campbell AS, Fraser-Reid B, Grusby MJ, Tachado SD. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science 1999; 283: 225-229
57. Fischer K, Scotet E, Niemeyer M, Koebernick H, Zerrahn J, Maillet S, Hurwitz R, Kursar M, Bonneville M, Kaufmann SH, Schaible UE. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc Natl Acad Sci USA 2004; 101: 10685-10690
58. Lang GA, Maltsev SD, Besra GS, Lang ML. Presentation of alpha-galactosylceramide by murine CD1d to natural killer T cells is facilitated by plasma membrane glycolipid rafts. Immunology 2004; 112: 386-396
59. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, Kondo E, Harada M, Koseki H, Nakayama T, Tanaka Y, Taniguchi M. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 1998; 95: 5690-5693
60. Stanic AK, De Silva AD, Park JJ, Sriram V, Ichikawa S, Hirabyashi Y, Hayakawa K, Van Kaer L, Brutkiewicz RR, Joyce S. Defective presentation of the CD1 d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiency. Proc Natl Acad Sci USA 2003; 100: 1849-1854
61. Margalit M, Ghazala SA, Alper R, Elinav E, Klein A, Doviner V, Sherman Y, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y. Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes. Am J Physiol Gastrointest Liver Physiol 2005; 289: G917-G925
62. Margalit M, Shalev Z, Pappo O, Sklair-Levy M, Alper R, Gomori M, Engelhardt D, Rabbani E, Ilan Y. Glucocerebroside ameliorates the metabolic syndrome in OB/OB mice. J Pharmacol Exp Ther 2006; 319: 105-110
63. Zigmond E, Preston S, Pappo O, Lalazar G, Margalit M, Shalev Z, Zolotarov L, Friedman D, Alper R, Ilan Y. Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders. Gut 2007; 56: 82-89
64. Ilan Y, Ohana M, Pappo O, Margalit M, Lalazar G, Engelhardt D, Rabbani E, Nagler A. Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T lymphocyte plasticity. Transplantation 2007; 93: 458-467
65. van Dieren JM, van der Woude CJ, Kuipers EJ, Escher JC, Samsom JN, Blumberg RS, Nieuwenhuis EE. Roles of CD1d-restricted NKT cells in the intestine. Inflamm Bowel Dis 2007; 13:1146-1152
66. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004; 113: 1490-1497
67. Numata Y, Tazuma S, Ueno Y, Nishioka T, Hyogo H, Chayama K. Therapeutic effect of repeated natural killer T cell stimulation in mouse cholangitis complicated by colitis. Dig Dis Sci 2005; 50: 1844-1851
68. + T cell trapping and NK1.1+ cells in liver-mediated immune regulation. Clin Immunol 2004; 111: 82-92
69. Shibolet O, Kalish Y, Klein A, Alper R, Zolotarov L, Thalenfeld B, Engelhardt D, Rabband E, Ilan Y. Adoptive transfer of ex vivo immune-programmed NKT lymphocytes alleviates immune-mediated colitis. J Leukoc Biol 2004; 75: 76-86
70. Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 1996; 183: 2605-2616
71. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002; 17: 629-638
72. Page MJ, Poritz LS, Tilberg AF, Zhang WJ, Chorney MJ, Koltun WA. Cd1d-restricted cellular lysis by peripheral blood lymphocytes: relevance to the inflammatory bowel diseases. J Surg Res 2000; 92: 214-221
73. Perera L, Shao L, Patel A, Evans K, Meresse B, Blumberg R, Geraghty D, Groh V, Spies T, Jabri B, Mayer L. Expression of nonclassical class I molecules by intestinal epithelial cells. Inflamm Bowel Dis 2007; 13: 298-307